Lv2
110 积分 2024-08-16 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
4小时前
待确认
Claudin 18.2 as a novel therapeutic target
1天前
已完结
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
5个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
5个月前
已完结
Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes
9个月前
已完结
PD‐L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy
9个月前
已完结
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
9个月前
已完结
The role of transcription factors in shaping regulatory T cell identity
9个月前
已完结
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
10个月前
已完结
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
10个月前
已完结
皖公网安备34019202002308
